[go: up one dir, main page]

DK1377667T3 - Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme - Google Patents

Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme

Info

Publication number
DK1377667T3
DK1377667T3 DK02714638T DK02714638T DK1377667T3 DK 1377667 T3 DK1377667 T3 DK 1377667T3 DK 02714638 T DK02714638 T DK 02714638T DK 02714638 T DK02714638 T DK 02714638T DK 1377667 T3 DK1377667 T3 DK 1377667T3
Authority
DK
Denmark
Prior art keywords
cancer
fusion proteins
autoimmune diseases
specific treatment
novel therapeutic
Prior art date
Application number
DK02714638T
Other languages
Danish (da)
English (en)
Inventor
Mathieu Hubertus Maria Noteborn
Ying-Hui Zhang
Johan Renes
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Application granted granted Critical
Publication of DK1377667T3 publication Critical patent/DK1377667T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02714638T 2001-03-30 2002-03-28 Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme DK1377667T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28022901P 2001-03-30 2001-03-30
PCT/NL2002/000204 WO2002079222A2 (en) 2001-03-30 2002-03-28 Fusion proteins for specific treatment of cancer and auto-immune diseases

Publications (1)

Publication Number Publication Date
DK1377667T3 true DK1377667T3 (da) 2009-03-30

Family

ID=23072205

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02714638T DK1377667T3 (da) 2001-03-30 2002-03-28 Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme

Country Status (9)

Country Link
US (1) US20020176860A1 (de)
EP (1) EP1377667B1 (de)
AT (1) ATE414776T1 (de)
AU (1) AU2002246455A1 (de)
DE (1) DE60229924D1 (de)
DK (1) DK1377667T3 (de)
ES (1) ES2321485T3 (de)
PT (1) PT1377667E (de)
WO (1) WO2002079222A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101921820B (zh) * 2010-02-10 2013-03-27 赵洪礼 具有活性重组肿瘤特异性凋亡因子的制备方法及其制品的应用
CN101875688B (zh) * 2010-02-10 2013-04-17 赵洪礼 重组肿瘤特异性凋亡因子制备方法中的叶酸化修饰步骤及其制品的应用
CA2822938A1 (en) 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
EP2760892A1 (de) 2011-09-29 2014-08-06 Apo-T B.V. Multispezifische bindungsmoleküle zur anzielung aberranter zellen
AU2013208364B2 (en) 2012-01-13 2017-10-26 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188832A1 (de) * 2000-09-08 2002-03-20 Leadd B.V. Verfahren zur Ablieferung der Tumor-spezifischen Apoptosis-auslösenden Aktivität von Apoptin
EP0878546A1 (de) * 1997-04-15 1998-11-18 Leadd B.V. Genabgabe-Vehikel die das Apoptosis VP2 inducierendes Protein, und/oder Apoptin exprimiert
PT830604E (pt) * 1995-06-07 2003-10-31 Leadd Bv Utilizacoes da apoptina
CA2301401C (en) * 1997-08-12 2008-10-21 Leadd B.V. Determining the transforming capability of agents
DE60003632T2 (de) * 1999-01-11 2004-04-15 Leadd B.V. Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1186665A1 (de) * 2000-09-08 2002-03-13 Leadd B.V. Verfahren zur Ablieferung der Tumor-spezifischen Apoptosis-auslösenden Aktivität von Apoptin
WO2002085305A2 (en) * 2001-04-24 2002-10-31 Washington University Compositions and methods for inducing cancer cell death

Also Published As

Publication number Publication date
EP1377667A2 (de) 2004-01-07
US20020176860A1 (en) 2002-11-28
ATE414776T1 (de) 2008-12-15
ES2321485T3 (es) 2009-06-08
EP1377667B1 (de) 2008-11-19
WO2002079222A2 (en) 2002-10-10
DE60229924D1 (de) 2009-01-02
WO2002079222A3 (en) 2003-05-08
PT1377667E (pt) 2009-03-13
AU2002246455A1 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
EP1194164B8 (de) Prion protein peptide und deren verwendung
MX2023004595A (es) Proteinas de fusion interleucina-2-fc y metodos de uso.
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
BR0209254A (pt) anticorpos de bloqueio cripto e usos dos mesmos
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
CY1105895T1 (el) Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης
EA200500218A1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
HK1145692A1 (zh) 人血管生成素- 的特異結合劑
CY1108489T1 (el) Παραγωγη τετρασθενων αντισωματων
DE60201783D1 (de) Pharmazeutische Zusammensetzung enthaltend nicht-MHC-abhängige T-Zellen/NK-Zellen und MHC-abhängige Zellen zur Behandlung von Tumoren
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
NO20055838L (no) Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
DE60204224D1 (de) Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
DK1377667T3 (da) Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
ATE481475T1 (de) Immunmodulation mit rezeptorinduziertem tod durch apoptosis
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
ATE395935T1 (de) An der oberfläche von karzinomzellen lokalisiertes colligin/hsp47
UY26170A1 (es) Antigeno (c42) asociados a tumores
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях